Live Breaking News & Updates on Monoclonal antibody specific

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Italy , Horsham , Saskatchewan , Canada , Spring-house , Pennsylvania , United-states , Milan , Lombardia , Japan , Canadian , Scandj-rheumatol

Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023

Horsham , Saskatchewan , Canada , Pennsylvania , United-states , Milan , Lombardia , Italy , Japan , Spring-house , Canadian , Zismand-comorbidities

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with.

Japan , United-states , Spring-house , British-columbia , Canada , Canadian , Craig-stoltz , Burrillb-crohn , Brucee-sands , Jan-wehkamp , American-college-of-gastroenterology-annual-meeting , Crohn-colitis-foundation

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou.

United-states , Japan , Calgary , Alberta , Canada , California , San-diego , Spring-house , British-columbia , Horsham , Saskatchewan , Americans

New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a.

New-york , United-states , Japan , Portland , Oregon , United-kingdom , Rockefeller-university , Horsham , Norfolk , Spring-house , British-columbia , Canada

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of.

Langley , British-columbia , Canada , Japan , Spring-house , United-states , Horsham , Saskatchewan , American , Jennifer-mcintyre , Alyssa-johnsen , Donvitot-creakyjoints

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021.

Canada , United-states , Japan , University-of-washington , Washington , Spring-house , British-columbia , Seattle , American , Jennifer-mcintyre , Alyssa-johnsen , Philipj-mease